We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'

Law360 (March 18, 2019, 11:11 PM EDT) -- AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.